link header image

"Buy 0.25 mg lanoxin visa, pulse pressure 60."

By: Joseph St. Geme, MD

  • Chair, Department of Pediatrics, Professor of Pediatrics and Microbiology, Perelman School of Medicine at the University of Pennsylvania
  • Physician-in-Chief, Leonard and Madlyn Abramson Endowed Chair in Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania


This interaction blood pressure normal values purchase lanoxin cheap online, one positron annihilation blood pressure medication bystolic side effects cheap 0.25 mg lanoxin amex, results in simultaneous emission of two photons blood pressure chart log purchase lanoxin 0.25 mg with mastercard, each having a specific energy (511 KeV) and emitted exactly 180° from each other blood pressure medication val buy lanoxin with amex. Therefore, two scintillation detectors are placed, one on either side of the tissue that contains the radionuclide. Detectors are connected to a coincident circuit that provides an output only when a certain level of gamma ray radiation can be simultaneously detected by both. The result is a low-background detector, highly specific for the particular radionuclide and providing excellent resolution. Radionuclides that undergo positron decay generally have very short half-lives. The resulting high count rates facilitate collection of statistically significant images in a very short time and a dynamic study of physiologic processes that produces a quick fluctuation in tissue concentrations of the tracer. The short half-lives also allow repeat image studies within a brief time with no confounding background activity from the prior injection. It is optimal to label radiopharmaceuticals using radionuclides with the shortest half-life that is compatible with the time scale of the physiologic process to be studied. However, a practical consequence of using short-lived (t1/2 < 1 hour) radionuclides in diagnostic medicine is the necessity for the radionuclide production and radiotracer synthesis to occur in the hospital where the imaging procedure will be conducted. In other markets, out of necessity, the production facility must be on site, and after rapid synthesis, the pharmaceutical must be purified. To date, very few positron emitters can be created by these systems, and only two radionuclides, 82Rb and 68Ga, have been extensively reported in the nuclear medicine literature. It is capable of distinguishing normal from abnormal myocardium in patients with suspected myocardial infarction, and it helps identify patients most likely to benefit from further intervention while reducing the risks of unnecessary medical, radiologic, and/or surgical procedures. The use of this infusion system is growing and is especially useful in obese/diabetic patients who have more adipose tissue which causes attenuation artifacts. A real perfusion defect may be exaggerated in size and severity using single photon emission computed tomography. Alternatively, a real perfusion defect can be hidden within an area of apparent attenuation. Typically, this generator was cost prohibitive unless the facility had a significant patient volume. Commercial nuclear pharmacies have developed a service that allows various departments to share a generator. Investigations have included radiolabeled antibiotics such as 18F-ciprofloxacin and 18F-fleroxacin (28). Attempts are being made to understand the mechanisms of binding and accumulation of radiopharmaceuticals to bacteria. Early clinical research has demonstrated that these may be useful for detecting metastases smaller than 1. About 2% to 4% of cancer patients have an initial diagnosis of cancer of unknown primary origin (29). For a single imaging procedure, an allowable dose (a dose that does not lead to excessive radiation exposure) may be significantly higher than these values. It undergoes a relatively long extraction into these organs and exhibits prolonged retention, as a major fraction of extractor tracer is metabolically incorporated into amino acids. For study of pulmonary ventilation, 13N gas is superior to the radioactive noble gases because of its lower solubility in blood. Glucose randomly labeled with 11C has been produced photosynthetically for use in studies of cerebral glucose metabolism. The use of 11C glucose for cerebral glucose metabolism requires imaging less than 5 minutes after injection. C15O can be safely administered via inhalation and serves as a tracer for red blood cell volume upon binding of the C15O to hemoglobin. H215O can be used in equilibrium studies of tissue water content and finds its greatest use as a tracer for regional blood flow. These are radioactive agents that terrorists might conceivably use to release from a dirty bomb that would be inhaled or ingested by victims. The two radioactive substances can cause serious illness and death when they gain entry, as the organs absorb high doses of radiation. Conventionally, 137Cs is used in a wide range of devices to treat certain cancers. Prussian blue was first manufactured in 1704 as a dye for Prussian military uniforms. To treat cesium and/or thallium radiation exposure, Prussian blue is administered orally in a dose of 3 g three times daily in adults and adolescents. It works by trapping cesium and thallium ions in the gastrointestinal tract and interrupts their reabsorption back into the systemic circulation. Prussian blue is not absorbed from the gastrointestinal tract to a significant degree. Compared to radiopharmaceuticals with a shorter half-life, this presents several distinct advantages for synthesis and allows delivery of the radionuclide to imaging centers at a distance from the generating cyclotron. It is taken up by cells, phosphorylated by hexokinase whose mitochondrial form is greatly elevated in rapidly growing malignant tumors, and is retained by tissues that demonstrate high metabolic activity. In cardiac studies, it identifies ischemic regions in which glucose metabolism increases as a consequence of decreased fatty acid metabolism. Preferably, it should be administered as soon as possible after exposure and is continued for 30 days. Food has been demonstrated to increase its effectiveness by stimulating bile secretion. Patients should be forewarned that constipation may occur, and if so, they should increase their dietary fiber. In addition, because the drug is a dye, it may discolor the stool blue, and if it is administered as a liquid or with bland food, it may discolor the lining of the mouth. It is important that pharmacists help the patient identify the source of the radiation and take appropriate safety measures to minimize exposure to others. Also, men should urinate in a stool rather than a urinal and flush the toilet several times after relieving themselves. Its use in cerebral perfusion studies is to enhance the differentiation between normal vessels and diseased vessels, which cannot easily dilate. It is indicated for use in patients with transient ischemic attack, carotid artery disease, or a cerebrovascular accident to help identify areas of the brain that are at risk for an infarct. Generally, radiopharmaceuticals used diagnostically help to monitor a physiologic process without altering it. Sometimes, however, the information gained from the procedure is inadequate to address the clinical questions. To overcome this deficiency, interventional pharmaceutical drugs are used to complement the radiopharmaceutical (34). These interventional pharmaceutical drugs alter the physiologic process being studied with radiopharmaceuticals. When the interventional drug is used in conjunction with nuclear medicine, the amount of information gained is greatly improved. This diverticulum, an abnormal remnant of the developing gastrointestinal tract, contains gastric mucosa that bleeds abnormally. This gastric mucosa concentrates 99mTc-pertechnetate as normal mucosa, and cimetidine. This results in an enhanced ability to visualize the small area of ectopic gastric mucosa. It inhibits the reabsorption of electrolytes, most notably sodium, in the ascending limb of the loop of Henle and in the proximal and distal tubules. In an obstructed kidney, furosemide diuresis will have little effect on clearance of the radioactivity retained in the kidney. An unobstructed kidney will rapidly clear the radioactivity into the bladder following furosemide administration, and the renograms will show rapid emptying with a steeply declining radioactivity curve. Typically, patients who are candidates to receive pharmaceutical stress as part of the imaging procedure rather than perform the stress test are those with cardiac, respiratory, and/or orthopedic problems, those maintained on beta-blocker or calcium channel blocker medications, and those with poor motivation. Dipyridamole blocks adenosine deaminase, the enzyme responsible for the degradation of adenosine, a potent coronary vasodilator. Adenosine can increase coronary blood flow up to four to five times the resting values. It possesses an ultra short half-life, less than 10 seconds, and is a potent coronary vasodilator. This drug can increase coronary blood flow four to five times that of rest and can be beneficial as a pharmaceutical stress agent to help diagnose and identify stenosed arteries.


  • Scarring or complications after surgical removal
  • Have you tried over-the-counter creams? Have they helped?
  • Your doctor gives you a shot of human chorionic gonadotropin (hCG)
  • Nausea and vomiting
  • The surgeon creates a pouch under your chest muscle.
  • Learn how to avoid triggers that make allergies worse

buy 0.25 mg lanoxin visa

Thesequentialadditionofprogestintoestrogenforat least 10 days of the cycle or continuous combined estrogen­progestogen does not increasetheriskofendometrialcancer blood pressure simulator order lanoxin 0.25mg. Womenonhormonetherapy should undergo annual monitoring blood pressure quizlet order 0.25mg lanoxin with amex, including pelvic examination blood pressure medication depression side effects buy cheap lanoxin 0.25 mg online, blood pressure checks pulse pressure and stroke volume purchase lanoxin 0.25mg without a prescription,androutineendometrialcancersurveillance. Plasma albumin concentrations decrease; thus volume of distributionofhighlyproteinbounddrugsmayincrease. Drugswithmolecularweightslessthan500Datransferreadily,drugswithmolecular weights from 600 to 1000 Da cross more slowly, and drugs with molecular weightsgreaterthan1000Da(eg,insulinandheparin)donotcrossinsignificant amounts. Use of nicotine replacement therapy during pregnancy is controversial; if used, intermittent delivery formulations (eg, gum) are preferred over patches. Proton pump inhibitors are options if response to histamine 2 (H2)­receptor blockers is inadequate. Dexamethasone and prednisolone have been effective for hyperemesis gravidarum (ie,severe nausea andvomitingcausing weight loss>5% of prepregnancy weight,dehydration,andketonuria),buttheriskoforalcleftsisincreased. Avoid aspirin in the third trimester, as it may also cause closureoftheductusarteriosus,maternalandfetalbleeding,anddecreaseduterine contractility. Sulfa-containing drugs may increase the risk for kernicterus in the newborn and should be avoided during the last weeks of gestation. Folate antagonists, such as trimethoprim, are relatively contraindicated during the first trimester because of their association with cardiovascular malformations. Symptoms in the neonate (eg, rhinitis, vaginitis, urethritis, ophthalmia neonatorum,andsepsis)usuallystartwithin2to5daysofbirth. Maternal use of acyclovir during the firsttrimesteris not associated withanincreasedriskofbirthdefects. Asstep1,allpregnantpatientswithasthma should have access toa short-acting inhaled 2-agonist (albuterolis the preferred agent). Completehealoccur3monthsafterchancroiddiagnosis ingdependsontheulcersize 500mgbymouththreetimes dailyЧ7days 1gbymouthЧ1dose500mg Test-of-cureat3weeksafter Gonorrhealcoinfectioncommon; bymouththreetimesdaily therapycompletion(exceptifin botharetreatedconcurrently Ч7days firsttrimester,thenretestafter Chlamydialinfectionisasymptomaticinmenand 3months) women Womenbelowage25yearsandthoseathighrisk. Commonly used agents are labetalol and hydralazine,buthydralazinecausesmorefetaladverseeffects. No evidence exists for the superior efficacy of one antihypertensive agent versus another, but drugs commonly used includelabetalol,methyldopa,andcalciumchannelblockers. Womenreceivingthyroidreplacement therapy before pregnancy may require increased dosage during pregnancy. Do not use oral terbutalineforthepreventionor treatmentofpretermlabor,asithasthesamerisksastheinjectableformbuthasnot beenshowntobeeffective. Five to 10 mg nifedipine may be administered sublingually every 15 to 20 minutes for three doses. Once stabilized, 10 to 20 mg may be administered orally every 4 to 6hoursforpretermcontractions. Antenatal Glucocorticoids ·A Cochrane review shows the benefit of antenatal corticosteroids for fetal lung maturation to prevent respiratory distress syndrome, intraventricular hemorrhage, anddeathininfantsdeliveredprematurely. Benefits from antenatal glucocorticoid administration are believed to beginwithin24hours. Patientcontrolled epidural analgesia results in a lower total dose of local anesthetic. Drugs with high molecular weights, lower lipid solubility, and higherproteinbindingarelesslikelytocrossintobreastmilk,ortheytransfermore slowlyorinsmalleramounts. Drugswithlongerhalf-livesare more likely to maintain higher levels in breast milk. Deficiency of intrinsic factor causes decreased absorption of vitamin B12 (ie, pernicious anemia). Acute-onsetanemiaischaracterizedbycardiorespiratorysymptoms such as tachycardia, light-headedness, and breathlessness. Chronic anemia is characterized by weakness, fatigue, headache, symptoms of heart failure, vertigo, faintness,coldsensitivity,pallor,andlossofskintone. Vitamin B12 and folate concentrations can be measured to differentiate between the two deficiency anemias. A vitamin B12 value less than 150 pg/mL (<111pmol/L),togetherwithappropriateperipheralsmearandclinicalsymptoms,is diagnosticofvitaminB12­deficiencyanemia. The dose and schedule of vitamin B12 should be titratedaccordingtotheclinicalandlaboratoryresponse. Neurologic symptoms can take longer to improve or can be irreversible, but should not progress during therapy. Hb begins to rise a week after startingvitaminB12therapyandshouldnormalizein1to2months. Additional contributing factors include functional asplenia (and increased risk of bacterial infection), deficient opsonization, and coagulation abnormalities. Symptoms are delayed until 4 to 6 months of age when HbS replaces fetal hemoglobin (HbF). Acute chest syndrome is characterized by pulmonary infiltration, respiratorysymptoms,andequivocalresponsetoantibiotictherapy. The most commontype isvasoocclusive crisis, whichis manifestedbypainovertheinvolvedareaswithoutchangeinHb. Interventionsincludegen·Routineimmunizationsplusinfluenza,meningococcal,andpneumococcalvaccina·Prophylactic penicillin is recommended until 5 years of age. Beginning at age 2 monthsorearlier,thedosageispenicillinVpotassium,125mgorallytwicedailyuntil 3yearsofageandthen250mgtwicedailyuntilage5years,orbenzathinepenicillin, 600,000unitsintramuscularlyevery4weeksfromage6monthsto6years. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Risksincludealloimmunization, hyperviscosity, viral transmission (requiring hepatitis A and B vaccination), volumeandironoverload,andtransfusionreactions. Meperidine should be avoided because accumulation of the normeperidine metabolite can cause neurotoxicity, especially in patients with impairedrenalfunction. Factors that minimize dependence include aggressive pain control, frequent monitoring, and taperingmedicationaccordingtoresponse. Jennifer Chan and Melissa FreiJones, for a more detailed discussion of this topic. An "empiric" antimicrobial regimen is begun before the offending organism is identified and sometimes before the documentation of the presenceofinfection,whereasa"definitive"regimenisinstitutedwhenthecausative organismisknown. Pain and Inflammation ·Painandinflammationmayaccompanyinfectionandaresometimesmanifestedby swelling, erythema, tenderness, and purulent drainage. M enal and hepatic function:Patientswithdiminishedrenaland/orhepaticfunction R willaccumulatecertaindrugsunlessthedosageisadjusted. Azalides: azithromycin; azoles: fluconazole, itraconazole, ketoconazole, and voriconazole; macrolides: erythromycin, clarithromycin; protease inhibitors: amprenavir, indinavir, lopinavir/ ritonavir, nelfinavir, ritonavir, and saquinavir; quinolones: ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin. Synergism ·Theachievementofsynergisticantimicrobialactivityisadvantageousforinfections ·Traditionally, combinations of aminoglycosides and -lactams have been used because these drugs together generally act synergistically against a wide variety of bacteria. Disadvantages of Combination Therapy ·Althoughtherearepotentiallybeneficialeffectsfromcombiningdrugs,therearealso potential disadvantages, including increased cost, greater risk of drug toxicity, and superinfectionwithevenmoreresistantbacteria. Failures Caused by Host Factors ·Patientswhoareimmunosuppressed(eg,granulocytopeniafromchemotherapyand acquiredimmunodeficiencysyndrome)mayrespondpoorlytotherapybecausetheir own defenses are inadequate to eradicate the infection despite seemingly adequate drugregimens. Ifthesesituationsarenotcorrected, they result in persistent infection and, occasionally, bacteremia, despite adequate antimicrobialtherapy. Failures Caused by Microorganisms ·Factors relatedtothe pathogen includethedevelopmentofdrugresistanceduring therapy. The most common causes of bacterial meningitis are Streptococcus pneumoniae, group B Streptococcus, Neisseria meningitidis, Haemophilus influenzae, and Listeria monocytogenes, ·The critical first step in the acquisition of acute bacterial meningitis is nasopharyngealcolonizationofthehostbythebacterialpathogen. Proteolytic products and toxic oxygen radicals cause an alteration of the blood­brain barrier, whereas platelet-activating factor activates coagulation, andarachidonicacidmetabolitesstimulatevasodilation. Continued therapy should be based on the assessment of clinical improvement, cultures, and susceptibilitytestingresults. Dexamethasone as an Adjunctive Treatment for Meningitis mentofpediatricmeningitis. Strength of recommendation: A, good evidence to support a recommendation for use; should always be offered; B, moderate evidence to support a recommendation for use; should generally be offered.

Lanoxin 0.25 mg for sale. 🍬The Myth & REAL Cause of High Blood Sugar & Diabetes - by Dr Sam Robbins.

buy generic lanoxin

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia heart attack movie online lanoxin 0.25 mg lowest price. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia xylazine arrhythmia buy discount lanoxin 0.25mg. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized arteria 3d castle pack 2 discount 0.25mg lanoxin with amex, double-blind blood pressure chart 3 year old discount 0.25mg lanoxin fast delivery, phase 2 trial. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Second-generation tyrosine kinase inhibitors, dasatinib and nilotinib, are active in most patients that have resistance or intolerance to imatinib. The typical clinical presentation of the chronic leukemias is an indolent course in contrast to patients with acute leukemia who will die of their disease within weeks to months if not treated. Bone marrow hyperplasia and accumulation of differentiated myeloid cells in the peripheral blood are the initial presenting features of the disease. Chronic myeloid leukemia was first described in 1845, but extensive research into the genetic and molecular characteristics of the disease began with the discovery of the Philadelphia chromosome (Ph) in 1960 by Nowell and Hungerford. Diagram of the chromosomal translocation that results in the Philadelphia chromosome. The progeny from this transformed primitive hematopoietic stem cell results in a proliferative advantage over normal hematopoietic cells that displaces normal hematopoiesis. Signs and symptoms include fatigue, sweating, bone pain, weight loss, abdominal discomfort, and early satiety secondary to splenomegaly. Symptoms secondary to leukostasis include acute abdominal pain resulting from splenic infarctions, priapism, retinal hemorrhage, cerebrovascular accidents, confusion, hyperuricemia, and gouty arthritis. Initial laboratory workup includes complete blood count with differential, complete metabolic panel, and serum uric acid. Bone marrow is markedly hypercellular (75%­90%) with increased granulocyte/erythroid ratio increased (10­30:1), erythropoiesis increased megakaryocytes normal. Accelerated phase is characterized by progressive myeloid maturation arrest and loss of efficacy of drug therapy directed to attenuate the increase in white blood cells. Nonspecific findings such as bone pain, fever, night sweats, and weight loss may occur. The most commonly observed cytogenetic changes with disease progression are an additional Ph chromosome, trisomy 8, and isochrome I(17q). However, this scoring system was developed prior to the advent of tyrosine kinase inhibitor therapy and may have limited predictive value in the era of imatinib. Cytogenetic responses are based on the percentage of cells positive for Ph in a bone marrow biopsy. Patients who have a major or complete cytogenetic response have an improved survival compared to those who fail to achieve a cytogenetic response. Historically, the two agents used for leukoreduction are busulfan (Myleran) and hydroxyurea (Hydrea). Busulfan is no longer used because randomized trials have shown that hydroxyurea treatment provides a modest survival advantage and busulfan has a risk of potentially life-threatening pulmonary fibrosis. The study was designed to allow crossover to the opposite treatment arm for lack of response or intolerance. At 60 months, the best observed rate of a major cytogenetic response and complete cytogenetic response while on imatinib was 89% and 82%, respectively. When the Sokal prognostic scoring system was used the complete cytogenetic response rates were 89%, 82%, and 69% in low-risk, intermediate-risk, and highrisk patients, respectively. Patients that do not achieve a hematologic response by 3 months, cytogenetic response by 6 months, or a major cytogenetic response by 12 months fare significantly worse compared to responders. The risk of disease progression according to the Sokal scoring system estimated the rates of disease progression to be 3%, 8%, and 17% in low-risk, intermediate-risk, and high-risk patients, respectively. However, the Sokal score was not associated with disease progression in patients who achieved a complete cytogenetic response. An open-label, non-randomized trial evaluated imatinib 400 mg daily with dose escalation to 600 mg daily and 400 mg twice daily (for patients not achieving a hematologic response after 1 month). Imatinib 600 mg was an independent predictive factor for the likelihood of a sustained hematologic response. Chronic Leukemias Imatinib Resistance Despite having high cytogenetic response rates, some patients treated with imatinib will not respond to therapy or will relapse after primary response. Resistance is caused by point mutations in one or more of several areas on the Abl kinase. The T315I mutation occurs directly within the imatinib binding site and completely disrupts imatinib binding. Algorithms for desensitization for patients that have experienced serious imatinibassociated rash have been published. After the liver function tests normalize, imatinib can be restarted at a reduced dose of not less than 300 mg per day. Imatinib is then dose escalated to the initial dose if liver function tests do not rise during 6 to 12 weeks of treatment. Death as a consequence of liver failure has been reported in a patient receiving large doses of acetaminophen concomitantly with imatinib. It is recommended that patients on imatinib limit their use of acetaminophen to 1,300 mg daily. During the phase I trial of imatinib, a patient who received concurrent phenytoin therapy developed a suboptimal response and was found to have a 75% reduction in plasma imatinib concentrations as compared to patients not receiving phenytoin. The clinical significance of this interaction was confirmed when disease control was acquired with the discontinuation of phenytoin. Imatinib has been reported to increase blood levels of cyclosporine and simvastatin. Other agents that should be closely monitored include aprepitant, dexamethasone, St. Recommendations for monitoring include baseline molecular and cytogenetic assessment. However, if a patient has not yet achieved a cytogenetic response at 12 months then bone marrow cytogenetic should be repeated at 18 months and as clinically indicated. However, imatinib also suppresses normal hematopoiesis, which suggests that myelosuppression associated with imatinib is probably related to effects on the Ph clone and normal hematopoietic cells. Nausea and vomiting is the event most commonly reported and can be managed by administering the drug with food. Higher doses of imatinib may be split in half and taken twice daily to reduce gastrointestinal side effects. Diarrhea may be dose related and can be controlled with antidiarrheal medications such as loperamide or diphenoxylate/atropine. Risk factors for edema include female gender, age older than 65 years, and a history of heart or kidney disease. Approximately 20% to 40% of patients complain of musculoskeletal symptoms, which tend to occur during the first month of therapy and decline in severity over time. Drug rash frequently occurs but is usually mild and can be managed with antihistamines or topical steroids. Preclinical data show that dasatinib is 300 times more potent than imatinib and has inhibitory activity in imatinib-resistant clones, with the exception of the T315I. The rate of complete cytogenetic response at 12 months was significantly higher with dasatinib as compared with imatinib (77% vs. The rate of major molecular response was also significantly higher in the dasatinib group (46% vs. Toxicities were similar between the two treatment groups, with the exception that 10% of dasatinib-treated patients developed grade 1 or 2 pleural effusions. Nilotinib has inhibitory activity against imatinib-resistant mutants with the exception of T315I. Both nilotinib arms had a significantly higher major molecular response rate at 12 months (43% and 44% for nilotinib 300 and 400 mg twice daily, respectively) as compared to imatinib (22%, P < 0. The number of patients discontinued from treatment was similar in all three treatment arms. Reversible myelosuppression is the most common side effect seen with dasatinib and nilotinib, and may require interruption of therapy. Side effects unique to dasatinib include fluid retention and pleural effusions, which appear to be related to peak drug concentrations.


  • Primary tubular proximal acidosis
  • Skandaitis
  • Bruck syndrome
  • Dermatocardioskeletal syndrome Boronne type
  • Spondylarthritis
  • Symphalangism, distal, with microdontia, dental pulp stones, and narrowed zygomatic arch
  • Hyperoxaluria type 2
  • Becker disease

Recent Issues

(For all back issues go to the Archive)




Founder/Publisher/Editor: David McGee
Contributing Editors: Billy Altman, Derk Richardson
Logo Design: John Mendelsohn (www.johnmendelsohn.com)
Website Design: Kieran McGee (www.kieranmcgee.com)
Staff Photographers: Audrey Harrod (Louisville, KY; www.flickr.com/audreyharrod), Alicia Zappier (New York)
E-mail: thebluegrassspecial@gmail.com
Mailing Address: David McGee, 201 W. 85 St.—5B, New York, NY 10024